Utility of octreoide as second line treatment in concurrent chemoradiation induced diarrhea: Preliminary results in 20 patients

Basit Öğe Kaydı
dc.authorscopusid55885460400
dc.authorscopusid6603453640
dc.contributor.authorTopkan E.
dc.contributor.authorSelek U.
dc.date.accessioned2024-08-04T20:01:12Z
dc.date.available2024-08-04T20:01:12Z
dc.date.issued2004
dc.departmentİnönü Üniversitesien_US
dc.description.abstractTo evaluate efficacy of octreotide in treatment of chemo-radiation induced diarrhea refractory to loperamide treatment. Our study consists of 20 intractable diarrhea patients that was resistant to loperamide, out of 33 rectum adenocarcinoma patients (T3-4NXM0) treated at Department of Radiation Oncology, Inonu University, between September 2002 and January 2003. All patients were treated with conventional radiotherapy (50.4 Gy, 1.8 Gy/fraction) with high-energy photons and concurrent 500mg/m_/week i.v. bolus 5FU. Twenty-four patients were recorded having Grade 3 or Grade 4 gastrointestinal toxicity during chemoradiation, according to National Cancer Institute Common Toxicity Criteria (NCI-CTC). Four patients who required parenteral support due to severe cramping, incontinence, gross bloody diarrhea were not included in the trial. Diarrhea failed to improve in 20 patients after 48 hours of per oral loperamide (4 mg tid) administration on outpatient basis. Twenty patients were assigned to receive octreotide (150 mg tid, Sandostatin, Novartis Pharma AG, Basel, Switzerland)) subcutaneously for 5 consecutive days. Complete resolution of diarrhea was considered therapeutic response, whereas partial or no response in 5 days of octreotide application was documented as failure. Diarrhea, recorded as NCI-CTC Grade 3 & 4, was largely experienced in the first two weekly cycles of 5FU administration concurrent with radiotherapy (80%). Subcutaneous octreotide application for 5 days resolved diarrhea completely in 17 patients out of 20 cases (85%) without any side effects (1-3 days, 15 patients-75%; 4-5 days, 2 patients-10%). Mean response period was 2.5 days. No side effects related with octreotide application was observed. Three irresponsive patients (15%) following 5 days of octreotide treatment were recorded as failure and were hospitalized to receive additional antidiarrheal agents, antibiotics, and parenteral fluid-electrolyte support; 2 cases recovered at 7th and 1 case recovered at 8th day. Daily subcutaneous octreotide application (150 mg tid) for five days seems to be an effective, tolerable second-line treatment for concurrent chemoradiation induced diarrhea refractory to loperamide.en_US
dc.identifier.endpage67en_US
dc.identifier.issn1301-8825
dc.identifier.issue2en_US
dc.identifier.scopus2-s2.0-3142746815en_US
dc.identifier.scopusqualityN/Aen_US
dc.identifier.startpage61en_US
dc.identifier.urihttps://hdl.handle.net/11616/91332
dc.identifier.volume14en_US
dc.indekslendigikaynakScopusen_US
dc.language.isotren_US
dc.relation.ispartofTHOD - Turk Hematoloji-Onkoloji Dergisien_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectChemotherapyen_US
dc.subjectDiarrheaen_US
dc.subjectOctreotiden_US
dc.subjectRadiotherapyen_US
dc.titleUtility of octreoide as second line treatment in concurrent chemoradiation induced diarrhea: Preliminary results in 20 patientsen_US
dc.title.alternativeEşzamanli kemoradyoterapiye ba?li diyarede i?kinci basamak tedavide oktreotid'in yeri: 20 Hastada ön sonuçlaren_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu